Patients who develop LN within 1 to 5 years after SLE onset may face poorer renal outcomes compared with those who develop the disease earlier.

To better compare belimumab’s efficacy with results from phase 3 trials of obinutuzumab, investigators conducted a post hoc analysis of patients with active proliferative lupus nephritis in the MMF ...

A subset of patients receiving triple immunosuppressive therapy with voclosporin, mycophenolate mofetil, and low-dose glucocorticoids can achieve lower proteinuria targets.

Negotiated reliance may offer a way to provide care to patients who resist efforts by clinicians and healthcare facilities.

The FDA has approved HemiClor (12.5 mg chlorthalidone) tablets for the treatment of hypertension in adults, to lower blood pressure.

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

The pledge comes as the United States plans to leave the international organization, The Washington Post reported.

Investigators aimed to identify an optimal PSA cut-off to define PSA persistence after prostate cancer surgery using new ultrasensitive assay methods.

Investigators present 48 month follow-up data from a phase 2b trial on padeliporfin vascular-targeted photodynamic therapy for intermediate-risk prostate cancer.

(HealthDay News) — Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnant women is a risk factor for preterm birth, according to a study published online May 9 in ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

The updated warnings highlight a rare risk of heart inflammation in teen boys and young men, CBS News reported.